text:  There's not yet much evidence about the risks and benefits of microdosing, especially in the case of psilocybin. Kilmer at Rand says the market for cannabis is very different than psychedelics, but he does see parallels to where cannabis was a decade ago. Now is the time for the federal government. Do they want to potentially get involved and shape what these state markets look like? Or do they want to stand on the sidelines and watch kind of this creation of a patchwork?